Verismo Therapeutics
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3675 Market St Ste 200, Philadelphia, Pe...Phone Number
(215) 989-4225Website
www.verismotherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Verismo Therapeutics
Verismo Therapeutics is pioneering CAR T-cell therapy for the treatment of solid tumors. This paradigm-shifting technology features a unique KIR-CAR construct that has been proven to reduce T-cell exhaustion and kill solid tumor models in in vivo studies.Explore more
Verismo Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
PA
Director, Corporate Development
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Verismo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Verismo Therapeutics launches new products
Check out if Verismo Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Verismo Therapeutics has new funding data
Click to see if Verismo Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Verismo Therapeutics
Website visits: Recent activity has been detected on your website
Check if Verismo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Verismo Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Verismo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Verismo Therapeutics
Find 2 more new buyers
Compare Similar Companies to Verismo Therapeutics
Compare insights from companies similar to Verismo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Verismo Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Verismo Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Verismo Therapeutics.
Verismo Therapeutics financials insights
Gather financial insights about Verismo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$16M
2023
Other Financing Round
$24M
2025
Other Financing Round
$4M
2026
Corporate Investment
$28M
Verismo Therapeutics Tech Stack
A closer look at the technologies used by Verismo Therapeutics
See more technologies
Most Recent Scoops
Partnership
Partnership, Research & Development, Clinical Systems, Business Development, Safety, Medical Research, Public Health, Clinical Operations, Health & Safety, Healthcare Operations, Healthcare Technology, Operations, Patient Experience
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Lateral Move
Executive Move
Executive Moves, Lateral Move
Verismo Therapeutics News & Media
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX)...Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy
Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches Early clinical case from CELESTIAL-301 trial, the first-in-human KIR-CAR clinical trial in patients with relapsed/refractory B cell non-Hodgkin lymphoma...Verismo Therapeutics' Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented at AACR 2026 Plenary Session
Early clinical data show a favorable safety profile and dose-dependent efficacy signals across initial dose level cohorts 1 - 3 in advanced solid tumors for potential first of its kind multi-chain KIR-CAR living medicine Preliminary data suggest on-tumor target biologic activity with...Verismo Therapeutics Announces $28M Financing
PHILADELPHIA, PA, Verismo Therapeutics, a clinical-stage CAR T cell therapy company, announced a $28 million investment from its parent company, HLB Innovation.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Verismo Therapeutics
Sign Up For FreeTo access detailed company insights
Verismo Therapeutics is pioneering CAR T-cell therapy for the treatment of solid tumors. This paradigm-shifting technology features a unique KIR-CAR construct that has been proven to reduce T-cell exhaustion and kill solid tumor models in in vivo studies.... Read More
